{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:43:33Z","timestamp":1790649813375,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To discuss <jats:italic>the role of benzydamine<\/jats:italic> in the prevention and treatment of radiation-induced oral mucositis (OM) in head and neck (H&amp;N) cancer patients. This document represents an <jats:italic>expert opinion paper<\/jats:italic> on indications and key-role aspects in <jats:italic>OM pathogenesis<\/jats:italic>, <jats:italic>prevention and treatment<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Oral mucositis<\/jats:title>\n                <jats:p>OM represents a common side effect of chemotherapy (CHT) and radiotherapy (RT). It consists in a painful erythema involving the oral cavity mucosa, which may progress to ulceration. Five biologically dynamic phases are considered crucial in mucositis: \u201cinitiation, signalling, amplification, ulceration and healing\u201d. Oral environment and microbiota are fundamental in mucositis development being involved in susceptibility to infections and in ulceration consequences. Different agents against mucositis have been studied and the use of benzydamine is strongly supported in literature. The Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC\/ISOO) guidelines recommend its use for the prevention of OM in H&amp;N patients undergoing RT and RT\/CHT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Benzydamine<\/jats:title>\n                <jats:p>Benzydamine is a local anti-inflammatory drug with analgesic properties. It can decrease TNF-\u03b1, IL-1\u03b2 and prostaglandin synthesis, also inhibiting leukocyte-endothelial interactions, neutrophil degranulation, vasodilation and vascular permeability. Literature agrees on the beneficial effects of benzydamine in preventing and reducing oral mucositis severity in H&amp;N cancer patients undergoing RT\/CHT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Mucositis represents a major concern in H&amp;N cancer patients and a clinical and economical issue. A multimodal and multidisciplinary approach is needed for its management. International guidelines recommend benzydamine for OM prevention and treatment in H&amp;N cancer patients, but further \u201creal world\u201d trials should be designed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-021-06048-5","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T22:02:42Z","timestamp":1614636162000},"page":"5701-5709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis"],"prefix":"10.1007","volume":"29","author":[{"given":"Ourania","family":"Nicolatou-Galitis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-0224","authenticated-orcid":false,"given":"Paolo","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ren\u00e9-Jean Bensadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"6048_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/s0167-8140(02)00404-8","volume":"66","author":"A Trotti","year":"2003","unstructured":"Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253\u2013262. https:\/\/doi.org\/10.1016\/s0167-8140(02)00404-8","journal-title":"Radiother Oncol"},{"key":"6048_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/1874079001104010007","volume":"4","author":"O Nicolatou-Galitis","year":"2011","unstructured":"Nicolatou-Galitis O, Kouloulias V, Sotiropoulou-Lontou A et al (2011) Oral mucositis, pain and xerostomia in 135 head and neck cancer patients receiving radiotherapy with or without chemotherapy. The Open Cancer Journal 4:7\u201317. https:\/\/doi.org\/10.2174\/1874079001104010007","journal-title":"The Open Cancer Journal"},{"key":"6048_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00520-010-0892-z","volume":"18","author":"RV Lalla","year":"2010","unstructured":"Lalla RV, Latortue MC, Hong C et al (2010) A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 18:985\u2013992. https:\/\/doi.org\/10.1007\/s00520-010-0892-z","journal-title":"Support Care Cancer"},{"key":"6048_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00520-005-0835-2","volume":"14","author":"O Nicolatou-Galitis","year":"2006","unstructured":"Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A, Dardoufas K, Kouloulias V, Kyprianou K, Kolitsi G, Skarleas C, Pissakas G, Papanicolaou VS, Kouvaris J (2006) Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer 14:44\u201351. https:\/\/doi.org\/10.1007\/s00520-005-0835-2","journal-title":"Support Care Cancer"},{"key":"6048_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00520-005-0006-5","volume":"14","author":"O Nicolatou-Galitis","year":"2006","unstructured":"Nicolatou-Galitis O, Athanassiadou P, Kouloulias V, Sotiropoulou-Lontou A, Dardoufas K, Polychronopoulou A, Gonidi M, Kyprianou K, Kolitsi G, Skarleas C, Pissakas G, Papanikolaou IS, Kouvaris J (2006) Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Support Care Cancer 14:753\u2013762. https:\/\/doi.org\/10.1007\/s00520-005-0006-5","journal-title":"Support Care Cancer"},{"key":"6048_CR6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/0360-3016(89)90964-4","volume":"16","author":"JB Epstein","year":"1989","unstructured":"Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ (1989) Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int J Radiat Oncol Biol Phys 16:1571\u20131575. https:\/\/doi.org\/10.1016\/0360-3016(89)90964-4","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6048_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.radonc.2013.03.021","volume":"107","author":"K De Ruyck","year":"2013","unstructured":"De Ruyck K, Duprez F, Werbrouck J et al (2013) A predictive model for dysphagia following IMRT for head and neck cancer: introduction of the EMLasso technique. Radiother Oncol 107:295\u2013299. https:\/\/doi.org\/10.1016\/j.radonc.2013.03.021","journal-title":"Radiother Oncol"},{"key":"6048_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.oraloncology.2018.10.006","volume":"86","author":"E Orlandi","year":"2018","unstructured":"Orlandi E, Iacovelli NA, Rancati T, Cicchetti A, Bossi P, Pignoli E, Bergamini C, Licitra L, Fallai C, Valdagni R, Cavallo A (2018) Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. Oral Oncol 86:266\u2013272. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.10.006","journal-title":"Oral Oncol"},{"key":"6048_CR9","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1002\/cncr.33100","volume":"126","author":"S Elad","year":"2020","unstructured":"Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P, for the Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC\/ISOO), Arany P, al-Azri AR, Blijlevens N, Hovan A, Fregnani E, Fulton J, Gueiros LA, Rouleau T, Coller JK, al-Dasooqi N, Wardill H, Ameringer S, Antunes HS, Bateman EH, Bektas K, Bensadoun RJ, ten Bohmer K, Brito-Dellan N, Castillo D, Chiang K, de Mooij C, Eilers J, Epstein J, Galiti D, Fall-Dickson JM, Gobbo M, Issa Hazboun H, Jensen SB, Johansen J, Joy J, Joy K, Kandwal A, Kataoka T, Keefe D, Loprinzi CL, Lubart R, Skripnik Lucas A, Majorana A, Mayo B, de Mooij C, Mori T, Nair RG, Nasr N, Nicolatou-Galitis O, Ottaviani G, Migliorati C, Pentenero M, Porcello L, Peterson D, Potting C, Raber-Durlacher J, van Sebille YZA, Soga Y, Sonis S, Stringer AM, Thorpe D, Tilly V, Tissing W, Toro JJ, Treister NS, Vaddi A, Weikel D, van de Wetering M, Zur E (2020) MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 126:4423\u20134431. https:\/\/doi.org\/10.1002\/cncr.33100","journal-title":"Cancer"},{"key":"6048_CR10","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1007\/s00520-019-04848-4","volume":"27","author":"CHL Hong","year":"2019","unstructured":"Hong CHL, Gueiros LA, Fulton JS et al (2019) Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Supp Care Cancer 27:3949\u20133967. https:\/\/doi.org\/10.1007\/s00520-019-04848-4","journal-title":"Supp Care Cancer"},{"key":"6048_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrc1318","volume":"4","author":"ST Sonis","year":"2004","unstructured":"Sonis ST (2004) The pathobiology of mucositis. Nat Rev Cancer 4:277\u2013284. https:\/\/doi.org\/10.1038\/nrc1318","journal-title":"Nat Rev Cancer"},{"key":"6048_CR12","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.oraloncology.2009.08.006","volume":"45","author":"ST Sonis","year":"2009","unstructured":"Sonis ST (2009) Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol Dec 45:1015\u20131020. https:\/\/doi.org\/10.1016\/j.oraloncology.2009.08.006","journal-title":"Oral Oncol Dec"},{"key":"6048_CR13","first-page":"3","volume":"5","author":"ST Sonis","year":"2007","unstructured":"Sonis ST (2007) Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5:3\u201311","journal-title":"J Support Oncol"},{"key":"6048_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.oraloncology.2006.03.014","volume":"43","author":"S Sonis","year":"2007","unstructured":"Sonis S, Haddad R, Posner M, Watkins B, Fey E, Morgan TV, Mookanamparambil L, Ramoni M (2007) Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 43:289\u2013300. https:\/\/doi.org\/10.1016\/j.oraloncology.2006.03.014","journal-title":"Oral Oncol"},{"key":"6048_CR15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.ijrobp.2016.08.047","volume":"96","author":"P Bossi","year":"2016","unstructured":"Bossi P, Bergamini C, Miceli R, Cova A, Orlandi E, Resteghini C, Locati L, Alfieri S, Imbimbo M, Granata R, Mariani L, Iacovelli NA, Huber V, Cavallo A, Licitra L, Rivoltini L (2016) Salivary cytokine levels and oral mucositis in head and neck cancer patients treated with chemotherapy and radiation therapy. Int J Radiat Oncol Biol Phys 96:959\u2013966. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.08.047","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6048_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/imr.12567","volume":"279","author":"JM Pickard","year":"2017","unstructured":"Pickard JM, Zeng MY, Caruso R, N\u00fa\u00f1ez G (2017) Gut microbiota: role in pathogen colonization, immune responses, and inflammatory disease. Immunol Rev 279:70\u201389. https:\/\/doi.org\/10.1111\/imr.12567","journal-title":"Immunol Rev"},{"key":"6048_CR17","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/1097-0142(197804)41:4%3C1610::aid-cncr2820410452%3E3.0.co;2-b","volume":"41","author":"GP Bodey","year":"1978","unstructured":"Bodey GP, Rodriguez V, Chang HY, Narboni (1978) Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer 41:1610\u20131622. https:\/\/doi.org\/10.1002\/1097-0142(197804)41:4%3C1610::aid-cncr2820410452%3E3.0.co;2-b","journal-title":"Cancer"},{"key":"6048_CR18","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1007\/s00520-019-04893-z","volume":"27","author":"J Bowen","year":"2019","unstructured":"Bowen J, Al-Dasooqi N, Bossi P et al (2019) (2019) The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer 27:4023\u20134033. https:\/\/doi.org\/10.1007\/s00520-019-04893-z","journal-title":"Support Care Cancer"},{"key":"6048_CR19","doi-asserted-by":"publisher","first-page":"E559","DOI":"10.1111\/1469-0691.12287","volume":"19","author":"Y Ye","year":"2013","unstructured":"Ye Y, Carlsson G, Barr Agholme M, Wilson JAL, Roos A, Henriques-Normark B, Engstrand L, Mod\u00e9er T, P\u00fctsep K (2013) Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study. Clin Microbiol Infect 19:E559\u2013E567. https:\/\/doi.org\/10.1111\/1469-0691.12287","journal-title":"Clin Microbiol Infect"},{"key":"6048_CR20","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1007\/s00253-014-5841-1","volume":"98","author":"T De Ryck","year":"2014","unstructured":"De Ryck T, Grootaert C, Jaspaert L et al (2014) Development of an oral mucosa model to study host-microbiome interactions during wound healing. Appl Microbiol Biotechnol 98:6831\u20136846. https:\/\/doi.org\/10.1007\/s00253-014-5841-1","journal-title":"Appl Microbiol Biotechnol"},{"key":"6048_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/1535370215595467","volume":"241","author":"BWA Vanhoecke","year":"2016","unstructured":"Vanhoecke BWA, De Ryck TRG, De Boel K et al (2016) Low-dose irradiation affects the functional behavior of oral microbiota in the context of mucositis. Exp Biol Med (Maywood) 241:60\u201370. https:\/\/doi.org\/10.1177\/1535370215595467","journal-title":"Exp Biol Med (Maywood)"},{"key":"6048_CR22","doi-asserted-by":"publisher","first-page":"e0126312","DOI":"10.1371\/journal.pone.0126312","volume":"10","author":"A Wang","year":"2015","unstructured":"Wang A, Ling Z, Yang Z, Kiela PR, Wang T, Wang C, Cao L, Geng F, Shen M, Ran X, Su Y, Cheng T, Wang J (2015) Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One 10:e0126312. https:\/\/doi.org\/10.1371\/journal.pone.0126312","journal-title":"PLoS One"},{"key":"6048_CR23","doi-asserted-by":"publisher","first-page":"104453","DOI":"10.1016\/j.oraloncology.2019.104453","volume":"99","author":"E Orlandi","year":"2019","unstructured":"Orlandi E, Iacovelli NA, Tombolini V, Rancati T, Polimeni A, de Cecco L, Valdagni R, de Felice F (2019) Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer. Oral Oncol 99:104453. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.104453","journal-title":"Oral Oncol"},{"key":"6048_CR24","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1007\/s00520-019-05084-6","volume":"28","author":"A Vesty","year":"2020","unstructured":"Vesty A, Gear K, Biswas K, Mackenzie BW, Taylor MW, Douglas RG (2020) Oral microbial influences on oral mucositis during radiotherapy treatment for head and neck cancer. Support Care Cancer 28:2683\u20132691. https:\/\/doi.org\/10.1007\/s00520-019-05084-6","journal-title":"Support Care Cancer"},{"key":"6048_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.radonc.2018.04.023","volume":"129","author":"J Hou","year":"2018","unstructured":"Hou J, Zheng H, Li P, Liu H, Zhou H, Yang X (2018) Distinct shifts in the oral microbiota are associated with the progression and aggravation of mucositis during radiotherapy. Radiother Oncol 129:44\u201351. https:\/\/doi.org\/10.1016\/j.radonc.2018.04.023","journal-title":"Radiother Oncol"},{"key":"6048_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ebiom.2017.02.002","volume":"18","author":"X-X Zhu","year":"2017","unstructured":"Zhu X-X, Yang X-J, Chao Y-L, Zheng HM, Sheng HF, Liu HY, He Y, Zhou HW (2017) The potential effect of oral Microbiota in the prediction of mucositis during radiotherapy for nasopharyngeal carcinoma. EBioMedicine 18:23\u201331. https:\/\/doi.org\/10.1016\/j.ebiom.2017.02.002","journal-title":"EBioMedicine"},{"key":"6048_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/odi.12224","volume":"21","author":"B Vanhoecke","year":"2015","unstructured":"Vanhoecke B, De Ryck T, Stringer A, Van de Wiele T, Keefe D (2015) Microbiota and their role in the pathogenesis of oral mucositis. Oral Dis 21:17\u201330. https:\/\/doi.org\/10.1111\/odi.12224","journal-title":"Oral Dis"},{"key":"6048_CR28","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1007\/s00520-012-1463-2","volume":"20","author":"AMGA Laheij","year":"2012","unstructured":"Laheij AMGA, de Soet JJ, von dem Borne PA, Kuijper EJ, Kraneveld EA, van Loveren C, Raber-Durlacher JE (2012) Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients. Support Care Cancer 20:3231\u20133240. https:\/\/doi.org\/10.1007\/s00520-012-1463-2","journal-title":"Support Care Cancer"},{"key":"6048_CR29","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3945\/jn.114.203430","volume":"145","author":"PE Pontoppidan","year":"2015","unstructured":"Pontoppidan PE, Shen RL, Cilieborg MS et al (2015) Bovine colostrum modulates myeloablative chemotherapy-induced gut toxicity in piglets. J Nutr 145:1472\u20131480. https:\/\/doi.org\/10.3945\/jn.114.203430","journal-title":"J Nutr"},{"key":"6048_CR30","doi-asserted-by":"publisher","first-page":"e39764","DOI":"10.1371\/journal.pone.0039764","volume":"7","author":"XB Lin","year":"2012","unstructured":"Lin XB, Dieleman LA, Ketabi A, Bibova I, Sawyer MB, Xue H, Field CJ, Baracos VE, G\u00e4nzle MG (2012) Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats. PLoS On 7:e39764. https:\/\/doi.org\/10.1371\/journal.pone.0039764","journal-title":"PLoS On"},{"key":"6048_CR31","doi-asserted-by":"publisher","first-page":"e82659","DOI":"10.1371\/journal.pone.0082659","volume":"8","author":"Y-D Nam","year":"2013","unstructured":"Nam Y-D, Kim HJ, Seo J-G, Kang SW, Bae J-W (2013) Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. PLoS One 8:e82659. https:\/\/doi.org\/10.1371\/journal.pone.0082659","journal-title":"PLoS One"},{"key":"6048_CR32","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00520-013-1741-7","volume":"21","author":"AM Stringer","year":"2013","unstructured":"Stringer AM, Al-Dasooqi N, Bowen JM et al (2013) Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer 21:1843\u20131852. https:\/\/doi.org\/10.1007\/s00520-013-1741-7","journal-title":"Support Care Cancer"},{"key":"6048_CR33","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s00248-013-0355-4","volume":"67","author":"E Montassier","year":"2014","unstructured":"Montassier E, Batard E, Massart S, Gastinne T, Carton T, Caillon J, le Fresne S, Caroff N, Hardouin JB, Moreau P, Potel G, le Vacon F, de la Cocheti\u00e8re MF (2014) 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high dose chemotherapy as conditioning regimen for bone marrow transplantation. Microb Ecol 67:690\u2013699. https:\/\/doi.org\/10.1007\/s00248-013-0355-4","journal-title":"Microb Ecol"},{"key":"6048_CR34","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1007\/s00520-019-04895-x","volume":"27","author":"S Elad","year":"2019","unstructured":"Elad S (2019) The MASCC\/ISOO Mucositis Guidelines 2019 Update: introduction to the first set of articles. Support Care Cancer 27:3929\u20133931. https:\/\/doi.org\/10.1007\/s00520-019-04895-x","journal-title":"Support Care Cancer"},{"key":"6048_CR35","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/cncr.28592","volume":"120","author":"RV Lalla","year":"2014","unstructured":"Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S, The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC\/ISOO) (2014) MASCC\/ISOO practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453\u20131461. https:\/\/doi.org\/10.1002\/cncr.28592","journal-title":"Cancer"},{"key":"6048_CR36","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1007\/s00520-019-04891-1","volume":"27","author":"V Ranna","year":"2019","unstructured":"Ranna V, Cheng KKF, Castillo DA et al (2019) Development of the MASCC\/ISOO clinical practice guidelines for mucositis: an overview of the methods. Support Care Cancer 27:3933\u20133948. https:\/\/doi.org\/10.1007\/s00520-019-04891-1","journal-title":"Support Care Cancer"},{"key":"6048_CR37","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/1097-0142(20010815)92:4%3C875::aid-cncr1396%3E3.0.co;2-1","volume":"92","author":"JB Epstein","year":"2001","unstructured":"Epstein JB, Silverman S Jr, Paggiarino DA et al (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92:875\u2013885. https:\/\/doi.org\/10.1002\/1097-0142(20010815)92:4%3C875::aid-cncr1396%3E3.0.co;2-1","journal-title":"Cancer"},{"issue":"8","key":"6048_CR38","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1006\/cyto.1996.0094","volume":"1996","author":"M Sironi","year":"1996","unstructured":"Sironi M, Pozzi P, Polentarutti N, Benigni F, Coletta I, Guglielmotti A, Milanese C, Ghezzi P, Vecchi A, Pinza M, Mantovani A (1996) Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokine 1996(8):710\u2013716. https:\/\/doi.org\/10.1006\/cyto.1996.0094","journal-title":"Cytokine"},{"key":"6048_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s005990070028","volume":"30","author":"M Sironi","year":"2000","unstructured":"Sironi M, Massimiliano L, Transidico P, Pinza M, Sozzani S, Mantovani A, Vecchi A (2000) Differential effect of benzydamine on pro- versus anti-inflammatory cytokine production: lack of inhibition of interleukin-10 and interleukin-1 receptor antagonist. Int J Clin Lab Res 30:17\u201319. https:\/\/doi.org\/10.1007\/s005990070028","journal-title":"Int J Clin Lab Res"},{"key":"6048_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/0976-237x.79292","volume":"2","author":"G Roopashri","year":"2011","unstructured":"Roopashri G, Jayanthi K, Guruprasad R (2011) Efficacy of benzydamine hydrochloride, chlorhexidine, and povidone iodine in the treatment of oral mucositis among patients undergoing radiotherapy in head and neck malignancies: a drug trail. Contemp Clin Dent 2:8\u201312. https:\/\/doi.org\/10.4103\/0976-237x.79292","journal-title":"Contemp Clin Dent"},{"key":"6048_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1365-2354.2008.00943.x","volume":"18","author":"A Kazemian","year":"2009","unstructured":"Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P (2009) Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care (Engl) 18:174\u2013178. https:\/\/doi.org\/10.1111\/j.1365-2354.2008.00943.x","journal-title":"Eur J Cancer Care (Engl)"},{"key":"6048_CR42","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/00002820-200609000-00012","volume":"29","author":"KKF Cheng","year":"2006","unstructured":"Cheng KKF, Ka Tsui Yuen J (2006) A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancer. Cancer Nurs 29:423\u2013430. https:\/\/doi.org\/10.1097\/00002820-200609000-00012","journal-title":"Cancer Nurs"},{"key":"6048_CR43","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00520-016-3548-9","volume":"25","author":"M Rastogi","year":"2017","unstructured":"Rastogi M, Khurana R, Revannasiddaiah S, Jaiswal I, Nanda SS, Gupta P, Chufal KS, Bhatt ML (2017) Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy. Support Care Cancer 25:1439\u20131443. https:\/\/doi.org\/10.1007\/s00520-016-3548-9","journal-title":"Support Care Cancer"},{"key":"6048_CR44","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1007\/s00520-013-1847-y","volume":"21","author":"O Nicolatou-Galitis","year":"2013","unstructured":"Nicolatou-Galitis O, Sarri T, Bowen J et al (2013) Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer 21:3179\u20133189. https:\/\/doi.org\/10.1007\/s00520-013-1847-y","journal-title":"Support Care Cancer"},{"key":"6048_CR45","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1007\/s00520-019-04888-w","volume":"27","author":"A Ariyawardana","year":"2019","unstructured":"Ariyawardana A, Cheng KKF, Kandwal A et al (2019) Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 27:3985\u20133995. https:\/\/doi.org\/10.1007\/s00520-019-04888-w","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06048-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T09:10:02Z","timestamp":1630487402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06048-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["6048"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06048-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]},"assertion":[{"value":"11 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval requested, being a review of published studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No consent needed, being a review of published studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No consent needed, being a review of published studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RJB and EO disclose no conflict of interest. ON-G reports personal fees from Angelini Pharma. PB reports that he has received advisory board or conference honoraria from Merck, Sanofi, Merck Sharp & Dohme, Sun Pharma, Angelini, Molteni, Bristol-Myers Squibb, Helsinn and GSK.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}